Revelation Biosciences (REVB) Gains from Investment Securities (2021 - 2025)
Revelation Biosciences (REVB) posted quarterly Gains from Investment Securities of -$87.0 for Q4 2025, up 96.6% year-over-year from -$44.25 in Q4 2024, and up 85.76% quarter-over-quarter from -$611.0 in Q3 2025.
Revelation Biosciences (REVB) Gains from Investment Securities (2021 - 2025) Analysis & Trends
Revelation Biosciences (REVB) has reported Gains from Investment Securities for 5 consecutive years, with -$87.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 96.6% year-over-year to -$87.0; the TTM figure through Dec 2025 stood at -$2159.0 (up 97.35% YoY), while the FY2025 annual figure was -$2158.0, up 97.35% from the prior year.
- Gains from Investment Securities climbed to -$87.0 in Q4 2025 per REVB's latest filing, from -$611.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $8.2 million in Q2 2022 and bottomed at -$7.7 million in Q1 2023.
- Historically, Gains from Investment Securities has averaged -$71891.6 across 5 years, with a median of -$4416.0 in 2024.
- Annual changes were most pronounced in 2022 — Gains from Investment Securities jumped 1570.23% — and 2023, when it sank 105.16%.
- Revelation Biosciences' Gains from Investment Securities stood at $246842.0 in 2021, then jumped by 3221.96% to $8.2 million in 2022, then slumped by 100.83% to -$68202.0 in 2023, then jumped by 96.25% to -$2557.0 in 2024, then surged by 96.6% to -$87.0 in 2025.
- Business Quant data shows REVB's Gains from Investment Securities at -$87.0 in Q4 2025, -$611.0 in Q3 2025, and -$44.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Revelation Biosciences | 4.17 Mn | -7.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -87.00 |
| Dec 31, 2025 | -87.00 |
| Sep 30, 2025 | -611.00 |
| Sep 30, 2025 | -611.00 |
| Jun 30, 2025 | -44.00 |
| Jun 30, 2025 | -44.00 |
| Mar 31, 2025 | -1,417.00 |
| Mar 31, 2025 | -1,417.00 |
| Dec 31, 2024 | -2,557.00 |
| Dec 31, 2024 | -2,557.00 |
| Sep 30, 2024 | -6,041.00 |
| Sep 30, 2024 | -6,041.00 |
| Jun 30, 2024 | -4,416.00 |
| Jun 30, 2024 | -4,416.00 |
| Mar 31, 2024 | -68,427.00 |
| Mar 31, 2024 | -68,427.00 |
| Dec 31, 2023 | -68,202.00 |
| Dec 31, 2023 | -68,202.00 |
| Sep 30, 2023 | -92,561.00 |
| Sep 30, 2023 | -92,561.00 |